Home›Stock Screener›Shilpa Medicare

Shilpa Medicare Share Price Today | Stock Price & Shilpa Medicare Share Screener

SHILPAMED Pharmaceuticals & Biotechnology
Live Share Price NSE
₹915.30
▼ -2.00 (-0.22%)
2026-11-18 00:00:00
Live Share Price BSE
₹916.10
▼ -0.90 (-0.10%)
2026-11-18 00:00:00

As of November 18, 2026, the live Shilpa Medicare share price (NSE: SHILPAMED) is ₹915.30 on NSE and ₹916.10 on BSE, down 0.22% from the previous close, with shares trading between ₹906.10 and ₹942.70 in today's trading session, and a 52-week range of ₹267.00–₹1,073.70. Track Shilpa Medicare marketcap in USD to gauge the company's total market size. Use the Shilpa Medicare stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Shilpa Medicare opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.

Key Statistics and Valuation Ratios

Over the trailing twelve months the company reported revenue of ₹538 and net income of ₹79, with EBITDA of ₹151, an operating margin of 27.0% and a profit margin of 14.7%.

Shilpa Medicare Market Cap ₹18,872.67 Cr.
SHILPAMED P/E Ratio (TTM) 58.40
Shilpa Medicare P/B Ratio 7.04
EPS (TTM) ₹12.44
Dividend Yield 0.06%
Debt to Equity 0.25
SHILPAMED 52 Week High ₹1073.70
Shilpa Medicare 52 Week Low ₹267.00
Operating Margin 27.00%
Profit Margin 14.68%
SHILPAMED Revenue (TTM) ₹538.00
EBITDA ₹151.00
Net Income ₹79.00
Total Assets ₹3,706.00
Total Equity ₹2,591.00

Shilpa Medicare Share Price Chart

Track the current stock price of Shilpa Medicare with an interactive chart. Analyse SHILPAMED share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Shilpa Medicare stock quote in one place.

The quote of ₹915.30 sits between the 52-week low of ₹267.00 and the 52-week high of ₹1,073.70, and the latest session moved -0.22% from the previous close.

Shilpa Medicare Company Profile - Fundamental Screener

Screen Shilpa Medicare company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for SHILPAMED shares across the equity market and its stock price history, plus the wider market trend.

The company is classified under the Healthcare sector and the Pharmaceuticals & Biotechnology industry, and it trades under ISIN INE790G01031.

Company Details

Classification

Sector Healthcare
Industry Pharmaceuticals & Biotechnology
Sub-Sector Pharmaceuticals & Biotechnology
Segment E

Identifiers and Leadership

ISIN INE790G01031

Shilpa Medicare Balance Sheet Screener

Screen SHILPAMED balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.

For 2026, total assets were ₹3,706, up from ₹3,311 in 2025.

Latest statistics put total assets at ₹3,706 and shareholder funds at ₹2,591, with a leverage ratio of 0.25.

Item 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017

Assets

Total Assets 3,706 3,311 3,093 2,904 2,876 2,632 1,989 1,610 1,499 1,472
Current Assets 0 0 0 0 0 0 0 0 0 0
Fixed Assets 1,593 1,418 1,385 1,368 1,342 1,111 650 558 534 492

Liabilities

Total Liabilities 0 0 0 0 0 0 0 0 0 0
Current Liabilities 266 273 600 345 453 561 257 167 154 251
Non-Current Liabilities 0 0 0 0 0 0 0 0 0 0

Shareholders' Equity

Total Equity 2,591 2,364 1,800 1,774 1,811 1,468 1,322 1,190 1,080 984
Share Capital 20 10 9 9 9 8 8 8 8 8
Reserves & Surplus 2,572 2,353 1,800 1,775 1,814 1,471 1,321 1,189 1,077 979

Shilpa Medicare Income Statement Screener - Profit & Revenue Analysis

Screen Shilpa Medicare income statement and profit fundamentals. Analyze SHILPAMED quarterly results. Shilpa Medicare reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.

For 2026-Sept, revenue was ₹538 and net profit was ₹79, equal to earnings per unit of ₹4.05, at an operating margin of 27%.

In that period expenses were ₹387, interest cost ₹13 and tax ₹24. The next period listed, 2026-Jun, shows revenue of ₹475 and net profit of ₹101.

Item 2026-Sept 2026-Jun 2026-Mar 2025-Dec 2025-Sept 2025-Jun 2025-Mar 2024-Dec 2024-Sept 2024-Mar 2024-Jun 2023-Mar 2023-Jun 2023-Sept 2023-Dec

Revenue and Expenses

Revenue 538 475 482 411 372 328 341 321 349 300 302 266 262 315 289
Expenses 387 330 317 309 262 231 282 239 258 222 223 227 214 255 222

Operating Costs and Margins

EBITDA 151 145 165 102 110 97 59 82 91 79 80 39 48 60 67
Operating Profit % 27.00% 29.00% 27.00% 25.00% 29.00% 28.00% 15.00% 25.00% 25.00% 24.00% 24.00% 14.00% 18.00% 19.00% 23.00%
Depreciation 34 35 31 30 30 29 29 29 28 27 27 26 27 28 27
Interest 13 12 14 11 16 19 15 12 26 24 24 18 18 23 26

Profit and Earnings

Profit Before Tax 104 98 120 61 64 50 15 42 37 28 29 -4 3 9 14
Tax 24 -3 13 16 20 3 1 10 19 3 15 4 2 8 10
Net Profit 79 101 108 45 44 47 15 32 18 25 14 -8 1 2 5
EPS 4.05 5.16 5.51 2.28 5.50 4.79 0.74 3.25 1.83 2.82 1.46 -0.93 0.14 0.19 0.53

Shilpa Medicare Cash Flow Screener - Liquidity Fundamentals

Screen SHILPAMED cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.

In 2026-March, operating activities generated ₹342, and net cash flow was an inflow of ₹17.

Over the same period, investing activities used ₹339 and financing activities provided ₹14.

Item 2026-March 2025-March 2024-March 2023-March 2022-March 2021-March 2020-March 2019-March 2018-March 2017-March

Cash from Operations and Investing

Operating Activities 342 132 137 180 105 47 124 147 45 38
Investing Activities -339 -198 -171 -232 -286 -404 -290 -196 -10 -257

Financing and Net Cash

Financing Activities 14 63 47 46 83 436 176 10 -61 313
Net Cash Flow 17 -3 13 -7 -98 79 10 -40 -26 93

Shilpa Medicare Shareholding Pattern Screener

See Shilpa Medicare shareholding pattern with promoter, FII, and DII holdings. Check Shilpa Medicare promoter holding and ownership changes for SHILPAMED on TickJournal, and see how institutional stock price moves affect the market.

In 2026-Sept, promoters held 40.13%, foreign institutions 12.11%, domestic institutions 8.26% and the public 27.73%, spread across 87,477 shareholders.

The shareholder count was 87,477 in 2026-Sept, compared with 60,926 in 2026-Jun.

Item 2026-Sept 2026-Jun 2026-Mar 2025-Dec 2025-Sept 2025-Jun 2025-Mar 2024-Dec

Promoter Holding

Promoter Holding 40.13% 40.13% 40.13% 40.13% 44.23% 44.23% 44.23% 44.23%

Institutional Investors

FII Holding 12.11% 11.38% 11.08% 10.97% 10.92% 11.20% 10.97% 9.90%
DII Holding 8.26% 8.05% 8.58% 8.33% 7.67% 7.46% 7.55% 8.27%

Government, Public and Others

Govt Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Public Holding 27.73% 27.67% 27.70% 27.80% 23.34% 23.21% 24.43% 24.40%
Other Holding 11.76% 12.76% 12.51% 12.76% 13.84% 13.90% 12.83% 13.21%
Shareholder Count 87,477 60,926 53,410 53,799 52,065 48,636 50,108 49,034

Dividend Yield Screener - Share Price & Share Analysis

Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Shilpa Medicare. Shilpa Medicare dividend yield can be compared with peers and other stocks in the market.

The latest dividend recorded was ₹0.60 per unit for 2026-March, a yield of 0.06%, compared with ₹1.00 for 2025-March.

Dividends are listed for 10 periods, with the three most recent payouts at ₹0.60, ₹1.00 and ₹0.00 per unit.

Period Dividend Per Share Dividend Yield
2026-March ₹0.60 0.06%
2025-March ₹1.00 0.29%
2024-March ₹0.00 0.00%
2023-March ₹0.00 0.00%
2022-March ₹1.10 0.96%
2021-March ₹1.10 0.55%
2020-March ₹1.10 0.66%
2019-March ₹1.00 0.82%
2018-March ₹0.70 0.41%
2017-March ₹0.60 0.26%

Shilpa Medicare Stock Index Membership - Nifty & Sensex

See which indices include Shilpa Medicare stock. Check SHILPAMED index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.

The company is listed in 5 indices, including BSE 1000.

Among the benchmarks tracked are BSE 1000, BSE INDEX BSE HC, BSE INDEX SMLCAP, NIFTY MICROCAP250.

Complete Index List

BSE 1000
BSE INDEX BSE HC
BSE INDEX SMLCAP
NIFTY MICROCAP250
NIFTY TOTAL MKT

Shilpa Medicare Market Events Screener - Corporate Actions

Get Shilpa Medicare corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Shilpa Medicare stock events that may affect SHILPAMED share price, along with derivatives, futures and options activity and sector gainers.

15 corporate actions are listed, the most recent entry being Quarterly Result Announcement dated November 5, 2026, with a record date of November 5, 2026.

It is followed by Annual General Meeting dated September 11, 2026 and Dividend dated September 4, 2026.

Announcement Date Record Date Event Type Information Price Impact
2026-11-05 2026-11-05 Quarterly Result Announcement NA 0.03%
2026-09-11 2026-09-11 Annual General Meeting NA 45.85%
2026-09-04 2026-09-04 Dividend ₹ 0.60 /share 101.23%
2026-08-05 2026-08-05 Quarterly Result Announcement NA 6.50%
2026-05-22 2026-05-22 Quarterly Result Announcement NA 8.35%
2026-02-06 2026-02-06 Quarterly Result Announcement NA 17.02%
2025-11-13 2025-11-13 Quarterly Result Announcement NA 11.79%
2025-10-03 2025-10-03 Bonus 1:1 -5.18%
2025-09-23 2025-09-23 Annual General Meeting NA -6.08%
2025-09-17 2025-09-17 Dividend ₹ 1.00 /share 5.73%
2025-08-13 2025-08-13 Quarterly Result Announcement NA 2.33%
2025-05-26 2025-05-26 Quarterly Result Announcement NA 10.39%
2025-02-10 2025-02-10 Quarterly Result Announcement NA 5.08%
2024-11-13 2024-11-13 Quarterly Result Announcement NA 3.95%
2024-09-17 2024-09-17 Annual General Meeting NA 26.59%

Shilpa Medicare Competitors Screener - Peer Stocks Comparison

Screen SHILPAMED competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.

The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.

Company Market Cap P/E Ratio Revenue YoY Growth Net Profit RSI
Sun Pharmaceutical 451,627 41.10 61,674 12.69% 11,565 63.60
Divis Laboratories 295,360 90.70 11,067 13.95% 2,568 78.53
Torrent Pharmaceuticals 178,781 84.50 13,886 20.34% 2,138 47.27
Laurus Labs 122,845 98.10 6,868 22.01% 890 69.60
Zydus Life Science 119,421 27.60 27,658 17.64% 5,026 52.34
Dr Reddys Laboratories 115,486 41.70 35,059 3.90% 4,158 70.24
Cipla 112,704 39.40 29,045 2.24% 3,870 54.92
Mankind Pharma 109,044 48.40 14,636 14.85% 1,938 65.43
Aurobindo Pharma 104,725 26.40 34,145 5.56% 3,503 66.06
Lupin 90,296 17.30 29,039 26.75% 5,356 44.92

Shilpa Medicare Company Announcements - News & Reports Screener

Screen SHILPAMED latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.

20 recent announcements are listed, the latest dated November 14, 2026.

The next most recent announcements are dated November 9, 2026 and November 9, 2026.

Date Update Actions
2026-11-14 Announcement under Regulation 30 (LODR)-Earnings Call Transcript -
2026-11-09 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome -
2026-11-09 Update On Corporate Insolvency Resolution Process Of FTF Pharma Private Limited A Wholly Owned Subsidiary Of Shilpa Medicare Limited. -
2026-11-09 Announcement under Regulation 30 (LODR)-Investor Presentation -
2026-11-09 Board Meeting Outcome for Outcome Of The Board Meeting Held On 05 November 2026 -
2026-11-05 Outcome Of The Board Meeting Held On 05 November 2026 -
2026-10-29 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation -
2026-10-29 Board Meeting Intimation for Approval Of Unaudited Financial Results For The 2Nd Quarter And Half Year Ended 30 September 2026. -
2026-10-10 Europe GMP Approval Of Shilpa Medicare Ltd. Unit 4 Jadcherla Telangana. -
2026-10-07 Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 -
2026-09-26 Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011. -
2026-09-25 Closure of Trading Window -
2026-09-23 Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Assignment Of ESG Rating By CRISIL ESG Ratings. -
2026-09-22 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation -
2026-09-18 USFDA Inspection Of Shilpa Medicare Limited Unit VII Analytical Services Division Hyderabad. -
2026-09-12 Shareholder Meeting / Postal Ballot-Scrutinizers Report -
2026-09-11 Announcement under Regulation 30 (LODR)-Press Release / Media Release -
2026-09-11 Shareholder Meeting / Postal Ballot-Outcome of AGM -
2026-09-10 Initiation Of NCLT Order On FTF Pharma Private Limited A Wholly Owned Subsidiary Of Shilpa Medicare Limited. -
2026-08-19 Dispatch Of Letter To Shareholders Whose E-Mail Addresses Are Not Registered With Company/Registrar & Transfer Agent /Depository Participants -

Frequently Asked Questions

How is the company valued right now?

The current quote is ₹915.30, within a 52-week range of ₹267.00 to ₹1,073.70. The P/E ratio is 58.40 and the P/B ratio is 7.04, with earnings per unit of ₹12.44. Market capitalisation stands at ₹18,872.67 Cr and the dividend yield is 0.06%. The company operates in the Healthcare sector, in the Pharmaceuticals & Biotechnology industry, so compare these ratios with its sector peers in the table above.

About This Data

Quotes are sourced from the NSE and the BSE. Key statistics were last updated on November 19, 2026. This page covers 10 balance sheet periods, 15 income statement periods, 10 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.